Drug Profile
Tafenoquine - GlaxoSmithKline/60 Degrees Pharmaceuticals
Alternative Names: 60P 003; Arakoda; Etaquine; KODATEF; Kozenis; Krintafel; SB-252263; SB-252263-AAB; SB-252263-AX; Tafenoquine maleate; Tafenoquine succinate; WR 238605; WR 238605 succinateLatest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Walter Reed Army Institute of Research
- Developer 60 Degrees Pharmaceuticals; Biocelect; GlaxoSmithKline; GSK; Medicines for Malaria Venture
- Class Aminoquinolines; Antifungals; Antimalarials; Antiprotozoals; Antivirals; Ethers; Fluorinated hydrocarbons; Small molecules
- Mechanism of Action Electron transport complex III inhibitors; Reactive oxygen species stimulants; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Marketed Malaria
- Phase II COVID 2019 infections
- Preclinical Babesiosis; Mycoses
- Discontinued Pneumocystis pneumonia
Most Recent Events
- 20 Feb 2024 60 Degrees Pharmaceuticals plans a Preclinical trial for Mycoses in Australia in the second quarter of 2024 (Parenteral)
- 26 Dec 2023 60 Degrees Pharmaceuticals plans a phase IIa trial in Babesiosis in USA (PO) in Q2 2024
- 26 Dec 2023 60 Degrees Pharmaceuticals plans a pre-IND meeting with the US FDA for Babesiosis before the end of 2023